Literature DB >> 33331329

[Co-existence of Guillain-Barré syndrome and Behcet syndrome: A case report].

C Yu1, C Li2, Y Y Fan3, Y Xu3.   

Abstract

A 40-year-old male patient was referred to our department with complains of recurrent oral ulcer for more than 20 years and vulvar ulcer for more than 10 years. He presented with a 3-month history of right external ophthalmoplegia. More than 10 days ago, the patient received ganglioside infusion. And one week ago, he developed numbness and pain of his lambs, and progressive myasthenia, accompanied by right blepharoptosis and dysuria. On exam, motor strength was graded 0/5 in the lower and the upper extremities. Deep tendon reflexes were diminished in extremities. His admission medical examination: hemoglobin (HGB), white cell and platelet counts were normal. C-reactive protein (CRP) was negative. Erythrocyte sedimentation rate (ESR) 53 mm/h. Antinuclear antibody (ANA), anti-dsDNA antibody, anti-Smith antibody, anti-cardiolipin antibody and human leucocyte antigen B51 were all within normal range. The etiological tests of influenza A pathogen, influenza B pathogen, parainfluenza virus, enterovirus and parvovirus were all negative. He tested positive for serum anti-GM1 IgG. Cerebrospinal fluid had a normal white cell count, an elevated protein content. Gram staining, culture and PCR detection for varicella-zoster virus, cytomegalovirus and herpes simplex virus were all negative. Antibodies associated with autoimmune encephalitis and paraneoplastic syndrome were negative in cerebrospinal fluid. Electromyography and nerve conduction studies showed a severe axonal damage affecting motor nerves. No obvious abnormalities were observed in his magnetic resonance imaging of brain and cavernous sinus. The patient was diagnosed with Behcet syndrome complicated with acute Guillain-Barré syndrome. He received intravenous methylprednisolone, intravenous immunoglobulin (IVIg) therapy, plasma exchange and rituximab treatment. After treatment, the patient's muscle strength of limbs was restored to grade 1, blepharoptosis and pain disappeared. The nervous system involvement of Behcet syndrome is relatively rare, especially combined with Guillain-Barré syndrome, which is easy to cause misdiagnosis. The treatment of Behcet syndrome complicated with acute Guillain-Barré syndrome includes the treatment of primary disease, plasma exchange and IVIg therapy. In addition, supportive treatment is very important for such patients. The focus of treatment is to avoid respiratory insufficiency, prevent deep vein thrombosis, monitor cardiac function and hemodynamics. Pain-relieving, physical exercise and psychological support are often under-recognized. The rehabilitation treatment is very important to improve the prognosis and quality of life of patients. What we need to learn is that when the symptoms and signs of the nervous system are difficult to be explained by neuro-Behcet syndrome alone, we should be alert to the possibility of other nervous system diseases.

Entities:  

Keywords:  Behcet syndrome; Case reports; Guillain-Barré syndrome; Immunoglobulins, intravenous

Mesh:

Substances:

Year:  2020        PMID: 33331329      PMCID: PMC7745265     

Source DB:  PubMed          Journal:  Beijing Da Xue Xue Bao Yi Xue Ban        ISSN: 1671-167X


  16 in total

Review 1.  Population incidence of Guillain-Barré syndrome: a systematic review and meta-analysis.

Authors:  James J Sejvar; Andrew L Baughman; Matthew Wise; Oliver W Morgan
Journal:  Neuroepidemiology       Date:  2011-03-21       Impact factor: 3.282

2.  Coexistence of Guillain-Barré syndrome and Behçet's disease.

Authors:  Erkingul Shugaiv; Asli Kiyat-Atamer; Erdem Tüzün; Feza Deymeer; Piraye Oflazer; Yesim Parman; Gulsen Akman-Demir
Journal:  Clin Exp Rheumatol       Date:  2013-02-25       Impact factor: 4.473

3.  Is there a decrease in Guillain-Barré syndrome incidence after bovine ganglioside withdrawal in Italy? A population-based study in the Local Health District of Ferrara, Italy.

Authors:  Vittorio Govoni; Enrico Granieri; Mauro Manconi; Jay Capone; Ilaria Casetta
Journal:  J Neurol Sci       Date:  2003-12-15       Impact factor: 3.181

Review 4.  Antibodies against gangliosides and ganglioside complexes in Guillain-Barré syndrome: new aspects of research.

Authors:  Susumu Kusunoki; Ken-ichi Kaida; Masami Ueda
Journal:  Biochim Biophys Acta       Date:  2007-10-12

Review 5.  Neuro-Behcet's disease: An update on diagnosis, differential diagnoses, and treatment.

Authors:  Afshin Borhani-Haghighi; Bahareh Kardeh; Shubhasree Banerjee; Golnaz Yadollahikhales; Anahid Safari; Mohammad Ali Sahraian; Lee Shapiro
Journal:  Mult Scler Relat Disord       Date:  2019-12-23       Impact factor: 4.339

6.  Systematic review of rituximab for autoimmune diseases: a potential alternative to intravenous immune globulin.

Authors:  John MacIsaac; Reda Siddiqui; Erin Jamula; Na Li; Steven Baker; Kathryn E Webert; Denise Evanovitch; Nancy M Heddle; Donald M Arnold
Journal:  Transfusion       Date:  2018-09-23       Impact factor: 3.157

7.  Curcumin Exerts Effects on the Pathophysiology of Alzheimer's Disease by Regulating PI(3,5)P2 and Transient Receptor Potential Mucolipin-1 Expression.

Authors:  Lu Zhang; Yu Fang; Xuan Cheng; Ya-Jun Lian; Hong-Liang Xu; Zhao-Shu Zeng; Hong-Can Zhu
Journal:  Front Neurol       Date:  2017-10-09       Impact factor: 4.003

Review 8.  Diagnosis and management of Neuro-Behçet's disease: international consensus recommendations.

Authors:  Seema Kalra; Alan Silman; Gulsen Akman-Demir; Saeed Bohlega; Afshin Borhani-Haghighi; Cris S Constantinescu; Habib Houman; Alfred Mahr; Carlos Salvarani; Petros P Sfikakis; Aksel Siva; Adnan Al-Araji
Journal:  J Neurol       Date:  2013-12-24       Impact factor: 4.849

Review 9.  Biological Drugs in Guillain-Barré Syndrome: An Update.

Authors:  Nazgol Motamed-Gorji; Nassim Matin; Omidreza Tabatabaie; Piero Pavone; Catia Romano; Raffaele Falsaperla; Giovanna Vitaliti
Journal:  Curr Neuropharmacol       Date:  2017       Impact factor: 7.363

Review 10.  Guillian-Barre syndrome as the initial presentation of systemic lupus erythematosus--case report and review of literature.

Authors:  Quaid Nadri; Mohammed Mahdi Althaf
Journal:  Ann Saudi Med       Date:  2015 May-Jun       Impact factor: 1.526

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.